SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2006.
  • 2
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
  • 3
    Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
  • 4
    Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004; 104: 3052-3057.
  • 5
    Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009; 101: 100-106.
  • 6
    Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111: 2962-2972.
  • 7
    Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995; 16: 7-11.
  • 8
    Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006; 106: 1084-1089.
  • 9
    Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009; 43: 417-422.
  • 10
    Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998; 21: 887-892.
  • 11
    Rosenbeck LL, Srivastava S, Kiel PJ. Peripheral blood stem cell mobilization tactics. Ann Pharmacother. 2010; 44: 107-116.
  • 12
    Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
  • 13
    Randles R, Wolfe D. Introduction to the Theory of Nonparametric Statistics: New York, NY: John Wiley & Sons; 1979.
  • 14
    Fisher R. On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
  • 15
    Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 16
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
  • 17
    Schwarz G. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
  • 18
    Venables WN, Ripley BD. Modern Applied Statistics With S-PLUS. 3rd ed. New York, NY: Springer; 1999.
  • 19
    Munshi NC, Anderson KC, Bergsagel PL, et al. Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-4700.
  • 20
    Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006; 91: 141-142.
  • 21
    Mikhael JR, Samiee S, Stewart K, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT [abstract]. Blood. 2007; 110. Abstract 946.
  • 22
    Simpson L, Verma R, Kumar S, Lacy M, et al. Outcome after second stem cell transplantation for relapsed multiple myeloma [abstract]. J Clin Oncol. 2007; 25. Abstract 8118.
  • 23
    Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma. 2009: 50: 1442-1447.
  • 24
    Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
  • 25
    Shah N, Weber D, Alexanian R, et al. Survival disparities between African-American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Paper presented at: American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, La.
  • 26
    Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001; 28: 29-37.
  • 27
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142.
  • 28
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132.
  • 29
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
  • 30
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
  • 31
    Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of 2 doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004; 127: 165-172.
  • 32
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25: 3892-3901.
  • 33
    Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008; 87: 623-631.
  • 34
    Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007; 92: 1149-1150.
  • 35
    Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007; 138: 330-337.
  • 36
    Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008; 26: 4777-4783.